Home > Research > Publications & Outputs > A comparison of methods for classifying samples...
View graph of relations

A comparison of methods for classifying samples as truly specific with confirmatory immunoassays

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

A comparison of methods for classifying samples as truly specific with confirmatory immunoassays. / Jaki, Thomas; Lawo, John-Philip; Wolfsegger, Martin J. et al.
In: Journal of Pharmaceutical and Biomedical Analysis, Vol. 88, 25.01.2014, p. 27-35.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Jaki, T, Lawo, J-P, Wolfsegger, MJ, Allacher, P & Horling, F 2014, 'A comparison of methods for classifying samples as truly specific with confirmatory immunoassays', Journal of Pharmaceutical and Biomedical Analysis, vol. 88, pp. 27-35. https://doi.org/10.1016/j.jpba.2013.08.013

APA

Jaki, T., Lawo, J-P., Wolfsegger, M. J., Allacher, P., & Horling, F. (2014). A comparison of methods for classifying samples as truly specific with confirmatory immunoassays. Journal of Pharmaceutical and Biomedical Analysis, 88, 27-35. https://doi.org/10.1016/j.jpba.2013.08.013

Vancouver

Jaki T, Lawo J-P, Wolfsegger MJ, Allacher P, Horling F. A comparison of methods for classifying samples as truly specific with confirmatory immunoassays. Journal of Pharmaceutical and Biomedical Analysis. 2014 Jan 25;88:27-35. Epub 2013 Sept 5. doi: 10.1016/j.jpba.2013.08.013

Author

Jaki, Thomas ; Lawo, John-Philip ; Wolfsegger, Martin J. et al. / A comparison of methods for classifying samples as truly specific with confirmatory immunoassays. In: Journal of Pharmaceutical and Biomedical Analysis. 2014 ; Vol. 88. pp. 27-35.

Bibtex

@article{93418fb226e9459bb35c87b9631dd480,
title = "A comparison of methods for classifying samples as truly specific with confirmatory immunoassays",
abstract = "Biotechnology-derived therapeutics may induce an unwanted immune response leading to the formation of anti-drug antibodies (ADAs) which can result in altered efficacy and safety of the therapeutic protein. Anti-drug antibodies may, for example, affect pharmacokinetics of the therapeutic protein or induce autoimmunity. It is therefore crucial to have assays available for the detection and characterization of ADAs. Commonly, a screening assay is initially used to classify samples as either ADA positive or negative. A confirmatory assay, typically based on antigen competition, is subsequently employed to separate false positive samples from truly positive samples. In this manuscript we investigate the performance of different statistical methods classifying samples in competition assays through simulation and analysis of real data. In our evaluations we do not find a uniformly best method although a simple t-test does provide good results throughout. More crucially we find that very large differences between uninhibited and inhibited measurements relative to the assay variability are required in order to obtain useful classification results questioning the usefulness of competition assays with high variability.",
author = "Thomas Jaki and John-Philip Lawo and Wolfsegger, {Martin J.} and Peter Allacher and Frank Horling",
year = "2014",
month = jan,
day = "25",
doi = "10.1016/j.jpba.2013.08.013",
language = "English",
volume = "88",
pages = "27--35",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - A comparison of methods for classifying samples as truly specific with confirmatory immunoassays

AU - Jaki, Thomas

AU - Lawo, John-Philip

AU - Wolfsegger, Martin J.

AU - Allacher, Peter

AU - Horling, Frank

PY - 2014/1/25

Y1 - 2014/1/25

N2 - Biotechnology-derived therapeutics may induce an unwanted immune response leading to the formation of anti-drug antibodies (ADAs) which can result in altered efficacy and safety of the therapeutic protein. Anti-drug antibodies may, for example, affect pharmacokinetics of the therapeutic protein or induce autoimmunity. It is therefore crucial to have assays available for the detection and characterization of ADAs. Commonly, a screening assay is initially used to classify samples as either ADA positive or negative. A confirmatory assay, typically based on antigen competition, is subsequently employed to separate false positive samples from truly positive samples. In this manuscript we investigate the performance of different statistical methods classifying samples in competition assays through simulation and analysis of real data. In our evaluations we do not find a uniformly best method although a simple t-test does provide good results throughout. More crucially we find that very large differences between uninhibited and inhibited measurements relative to the assay variability are required in order to obtain useful classification results questioning the usefulness of competition assays with high variability.

AB - Biotechnology-derived therapeutics may induce an unwanted immune response leading to the formation of anti-drug antibodies (ADAs) which can result in altered efficacy and safety of the therapeutic protein. Anti-drug antibodies may, for example, affect pharmacokinetics of the therapeutic protein or induce autoimmunity. It is therefore crucial to have assays available for the detection and characterization of ADAs. Commonly, a screening assay is initially used to classify samples as either ADA positive or negative. A confirmatory assay, typically based on antigen competition, is subsequently employed to separate false positive samples from truly positive samples. In this manuscript we investigate the performance of different statistical methods classifying samples in competition assays through simulation and analysis of real data. In our evaluations we do not find a uniformly best method although a simple t-test does provide good results throughout. More crucially we find that very large differences between uninhibited and inhibited measurements relative to the assay variability are required in order to obtain useful classification results questioning the usefulness of competition assays with high variability.

U2 - 10.1016/j.jpba.2013.08.013

DO - 10.1016/j.jpba.2013.08.013

M3 - Journal article

VL - 88

SP - 27

EP - 35

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

ER -